Standout Papers

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy 2014 2026 2018 2022 3.6k
  1. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy (2017)
    Padmanee Sharma, Siwen Hu‐Lieskovan et al. Cell
  2. The future of immune checkpoint therapy (2015)
    Padmanee Sharma, James P. Allison Science
  3. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential (2015)
    Padmanee Sharma, James P. Allison Cell
  4. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial (2017)
    Padmanee Sharma, Margitta Retz et al. The Lancet Oncology
  5. PD-L1 Expression in Triple-Negative Breast Cancer (2014)
    Elizabeth A. Mittendorf, Anne V. Philips et al. Cancer Immunology Research
  6. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021)
    Golnaz Morad, Beth A. Helmink et al. Cell
  7. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade (2017)
    Spencer C. Wei, Jacob Levine et al. Cell
  8. Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy (2016)
    Jianjun Gao, Lewis Z. Shi et al. Cell
  9. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial (2016)
    Padmanee Sharma, Margaret K. Callahan et al. The Lancet Oncology
  10. Immune checkpoint therapy—current perspectives and future directions (2023)
    Padmanee Sharma, Sangeeta Goswami et al. Cell
  11. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011)
    Padmanee Sharma, Klaus W. Wagner et al. Nature reviews. Cancer
  12. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer (2018)
    Yelena Y. Janjigian, Johanna C. Bendell et al. Journal of Clinical Oncology
  13. The Next Decade of Immune Checkpoint Therapy (2021)
    Padmanee Sharma, Bilal A. Siddiqui et al. Cancer Discovery
  14. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer (2017)
    Jianjun Gao, John F. Ward et al. Nature Medicine
  15. Effective combinatorial immunotherapy for castration-resistant prostate cancer (2017)
    Xin Lü, James W. Horner et al. Nature
  16. Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial (2010)
    Bradley Curtis Carthon, Jedd D. Wolchok et al. Clinical Cancer Research
  17. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study (2017)
    Hans J. Hammers, Elizabeth R. Plimack et al. Journal of Clinical Oncology
  18. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome (2007)
    Xingxing Zang, R. Houston Thompson et al. Proceedings of the National Academy of Sciences
  19. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers (2018)
    Anu Sharma, Sumit K. Subudhi et al. Clinical Cancer Research
  20. Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors? (2014)
    Chad Tang, Xiaohong Wang et al. Cancer Immunology Research
  21. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy (2014)
    Xiaozhou Fan, Sergio A. Quezada et al. The Journal of Experimental Medicine
  22. Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy (2018)
    Sangeeta Goswami, Irina Apostolou et al. Journal of Clinical Investigation

Immediate Impact

24 by Nobel laureates 53 from Science/Nature 169 standout
Sub-graph 1 of 16

Citing Papers

Natural killer cell therapies
2024 StandoutNature
SOX17 enables immune evasion of early colorectal adenomas and cancers
2024 StandoutNature
10 intermediate papers

Works of Padmanee Sharma being referenced

Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
and 11 more

Author Peers

Author Last Decade Papers Cites
Padmanee Sharma 19463 13562 5594 6273 254 27.6k
Elizabeth M. Jaffee 18074 15555 3765 9061 376 29.9k
Jennifer A. Wargo 15446 8004 3516 11019 260 24.6k
Matthew F. Krummel 10983 17393 2840 6211 162 26.6k
Silvia C. Formenti 15199 9581 6295 4992 346 26.4k
Sara Y. Brucker 18296 8988 6509 7129 125 27.5k
Eva‐Maria Grischke 20398 8977 8263 7490 122 29.0k
Robert H. Vonderheide 14819 13907 2360 6700 221 24.3k
Andreas D. Hartkopf 19125 8923 6723 7075 162 26.7k
Janis M. Taube 15222 7799 4715 3564 203 20.2k
Sandra Demaria 14383 10343 4715 3523 191 21.1k

All Works

Loading papers...

Rankless by CCL
2026